[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100304506":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":60,"collaborators":42,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":42,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":42,"enrollmentInfo":73,"targetDuration":42,"studyType":76,"phases":77,"briefSummary":80,"conditions":81,"keywords":42,"overallStatus":83,"whyStopped":42,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Zion Therapeutics, LLC","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group","ACTIVE_COMPARATOR","Intracameral injection of moxifloxacin solution after cataract surgery",[13],"Drug: Moxifloxacin",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo group","PLACEBO_COMPARATOR","Intracameral injection of placebo after cataract surgery",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Moxifloxacin","Intracameral injection",[9],[27],"active",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Placebo","intracameral injection",[15],[33],"sham",[35],{"name":36,"affiliation":5,"role":37},"Jason Ahee, M.D.","PRINCIPAL_INVESTIGATOR",[39],{"name":36,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","435-862-9865",null,"aheejason@hotmail.com",[45],{"facility":46,"status":42,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Zion Eye Institute","St. George","Utah","84790","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-113.58412,37.10415,{"lat":56,"lon":55},[59],{"name":36,"role":40,"phone":42,"phoneExt":42,"email":42},{"type":61,"investigatorFullName":36,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"SPONSOR_INVESTIGATOR","Medical Director","100304506","phase-2-safety-and-efficacy-of-intracameral-zimoxin-for-prevention-of-endophthalmitis-after-cataract-surgery-100304506",false,"NCT03244072","Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery","Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery","Inclusion Criteria:\n\n* visually significant cataracts\n\nExclusion Criteria:\n\n* allergy to fluoroquinolones, cobalamin (B12)",true,"ALL","40 Years",{"count":74,"type":75},60000,"ESTIMATED","INTERVENTIONAL",[78,79],"PHASE2","PHASE3","Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis",[82],"Endophthalmitis","NOT_YET_RECRUITING","2025-09-21",{"date":86,"type":87},"2025-09-25","ACTUAL",{"date":89,"type":75},"2026-06-01",{"date":91,"type":75},"2031-10",{"name":36,"class":6},1]